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Abstract 
Systemic Arterial Hypertension (SAH) is a risk factor for 9.4 million deaths worldwide. In Brazil, the condition attributes an annual 
cost of approximately USD640,000,000 to the SUS. The epidemiological and economic analysis of Pharmaceutical Care (PC) in 
the management of hypertensive patients showed an improvement in blood pressure control, a reduction of the risk of SAH 
complications, and an investment return of over USD1.7 million after ten years. Therefore, this article aims to present a 
pharmacoeconomic tool capable of assisting decision making in the implementation of PC in the SUS. A systematic review is being 
conducted for the robustness of the estimation of clinical and epidemiological impact of SAH, its results will be tabulated and 
applied in the improvement of the tool together with the direct medical and non-medical costs, indirect costs and costs of the SAH. 
In addition, a Markov model will be designed to estimate the incidence of cardiovascular diseases and SAH’s associated diseases 
by studies of proteomics that address the Human Network Disease. We hope to validate this auxiliary tool and thus to improve 
blood pressure control among hypertensive patients, quality of life, to reduce comorbidi ies nd deaths, as well as optimizing th
use of health resources. 
© 2017 The Authors. Published by Elsevier B.V. 
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Nomenclature 
CVD Cardiovascular Diseases 
PC Pharmaceutical Care 
SAH Systemic Arterial Hypertension 
SIASUS Information System of Outpatient (Sistema de Informações Ambulatórias do SUS) 
SIH Information System of Hospital Admissions (Sistema de Informações de Internações Hospitalares) 
SUS Unified Health System (Sistema Único de Saúde) 
WHO World Health Organization 
1. Introduction 
According to the WHO1, of 56.4 million deaths worldwide in 2015, 39.5 million were due to non-communicable 
diseases and almost 75% of these deaths occur in low- and middle-income countries. In Brazil, they account for the 
highest rates of morbidity and mortality and for a significant portion of outpatient and hospital care expenses which 
represent 70% of health care expenditures in the country2,3. SAH is among the most important non-communicable 
morbidities which is a multifactorial condition characterized by elevated and sustained blood pressure levels3,4. 
SAH affects about a third of the Brazilian population, reaching more than 50% of the elderly individuals and 5% 
of the children and adolescents. Its severity is related to the damage of target organs, such as kidneys, heart and 
brain1,5,6. According to the WHO7 SAH is considered a major risk factor for the occurrence of CVD. The increase of 
10 mmHg in systolic blood pressure increases by up to 25% the risk of developing CVD8. 
This context delineates a reality in which investment to improve access to health and treatment in the case of SAH 
has not shown the expected effectiveness9,10. This is exacerbated by the underfunding of the Brazilian Public Health 
System, the SUS, and its difficulties at improving the use of health resources. Hence, the SUS has sought alternatives 
to overcome this panorama of hypertension in Brazil, outlining strategies and care proposals that promote the 
improvement of clinical outcomes and patient care, and seeking health technologies that are capable of being integrated 
into pre-existing health services11. A health technology that has shown effectiveness in the control of chronic diseases 
such as hypertension12,13,14, and can optimize health resources is the PC15,16. 
PC is a model of professional practice where the pharmacist promotes patient care through consultations for 
pharmacotherapeutic follow-up. Some studies have shown that PC has been effective not only in blood pressure control 
but also in the reduction of health complications caused by hypertension13,17,18,19,20. As evidenced by Souza et al. 
(2007)21 this practice can reduce systolic blood pressure by 20 mmHg and diastolic blood pressure by 10 mmHg in 
hypertensive patients. 
In this context, this article aims to present a pharmacoeconomic tool capable of predicting the epidemiological and 
economic impact for the planning of the care of hypertensive patients by the PC in the SUS with proposed methods to 
its improvement and validation and, thus, to help reduce the morbidity and mortality associated with SAH and to 
improve the use of resources in health. 
In the next section, we will present some background information for the construction of the proposed tool. Then, 
in the third section, we will describe the steps taken and planned to build the system. At last, in the section four, we 
will present a brief description of the importance of such work. 
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the management of hypertensive patients showed an improvement in blood pressure control, a reduction of the risk of SAH 
complications, and an investment return of over USD1.7 million after ten years. Therefore, this article aims to present a 
pharmacoeconomic tool capable of assisting decision making in the implementation of PC in the SUS. A systematic review is being 
conducted for the robustness of the estimation of clinical and epidemiological impact of SAH, its results will be tabulated and 
applied in the improvement of the tool together with the direct medical and non-medical costs, indirect costs and costs of the SAH. 
In addition, a Markov model will be designed to estimate the incidence of cardiovascular diseases and SAH’s associated diseases 
by studies of proteomics that address the Human Network Disease. We hope to validate this auxiliary tool and thus to improve 
blood pressure control among hypertensive patients, quality of life, to reduce comorbidities and deaths, as well as optimizing the 
use of health resources. 
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2. Background 
The planning of the care of hypertensive patients by PC was structured in a proposal of pharmacoeconomic tool. 
This tool was grounded in a previous study, which has evidenced the reach of 98% of blood pressure control associated 
with PC and the reduction of 30.3% in cardiovascular risk in ten years22. The study presented an economic 
methodology of analysis, which was based on the development of a Markov model to predict the incidence and deaths 
from CVD and chronic kidney disease in a long time.  
Markov modeling is a mathematical tool attributed to the analysis of pharmacoeconomic decisions with the purpose 
of designing health states and death to predict complications of a treatment. This mathematical model is widely used 
for chronic diseases since they constitute more complex outcomes over a long period of time. With the application of 
the model, it is possible to attribute health state transitions over the years, determined by Markov cycles, which allows 
projection according to probabilities in a time horizon and, in the end, to obtain the individuals allocated in different 
health states, including the state of absorption (death), thus enabling the calculation of the years of life saved by 
different health technologies. For each health condition a cost can be assigned to perform pharmacoeconomic analyzes 
comparing different medications or interventions23,24. 
Therefore, the study of Cazarim25 measured the reduction in health costs associated with PC, showing a growing 
savings in health resources over a period of ten years. The liquid return of the investment in this pharmaceutical 
practice was USD $1,712,709.74 and the cost-benefit ratio was 30.03 (26.74 - 34.28), with the rate of return of 
investment of 303%. This has fostered the development of a pharmacoeconomic tool that can help health managers in 
the implementation of PC in the SUS, as well as in the allocation of health resources and epidemiological planning for 
hypertension and associated complications (chronic kidney disease, heart failure, ischemic heart disease, stroke and 
peripheral artery disease).  
For the improvement of the tool, an important point to be incorporated in a separate module are the costs of the 
morbidities associated with the complications of SAH which are not correlated to their treatment, not being considered 
the effect of SAH as a risk factor. This association of one disease as predisposing factor to another morbidity has been 
studied by a recent line of research, the Human Network Disease26. The approach and development of this line of 
research is done by methods of proteomic studies27, which are based on the mapping of proteins transcribed by mRNA 
precursors of diseases. This mapping is visualized in an integrated network form between diseases, which determines 
the association between their predisposition26. 
This modern conceptualization of the association between diseases has brought advances and expectations for 
treatments by the prospects of customizing medicine and making health care more preventive and effective. Because 
an avoided disease can prevent numerous other morbidities, and the disease initially avoided is not considered a risk 
factor for the others 26,28,29,30. 
The prevention of associated diseases can have a positive epidemiological and financial impact on the SUS. This 
impact has not been measured in the literature. However, this reinforces the need to create methods that evaluate and 
collaborate for the scientific development of the recent area. In addition, the measurement of the epidemiological and 
financial impact incorporated into the pharmacoeconomic tool tends to contribute to health planning, resources saving 
and optimization of the application of resources in health. In this context, we hypothesize that clinical results achieved 
by PC programs for hypertensive patients can avoid related complications, such as CVDs, and morbidities that have 
been associated with their complications. Moreover, this analysis incorporated in the development of the 
pharmacoeconomic tool can predict the epidemiological and economic impact associated with the implementation of 
PC in ten years, it collaborates for the reduction of morbidity and mortality associated with SAH and, consequently, 
for the planning of the application of resources in the SUS. 
3. Methods 
The pharmacoeconomic tool was developed according to the methods reported in the previous work of Cazarim25. 
A systematic review is being performed and its finds will be tabulated and applied to restructure the tool. In addition, 
a Markov model to estimate the incidence of diseases that has been associated with the complications of SAH will be 
structured. The probabilities for the model will be calculated according to the epidemiological indicators extracted 
from the diseases associations of proteomic studies. This serves to create a new field in the tool that assists a projection 
4 Maurílio de Souza Cazarim et al / Procedia Computer Science 00 (2017) 000–000 
of the epidemiological impact and morbidity costs. With this, the tool will be improved for its validation and 
applicability. The steps to elaborate the tool were are presented in Fig. 1. 
 
 
Fig. 1 Schematic diagram of the elaboration of the economic tool. 
3.1. Programming and development of the pharmacoeconomic tool 
The previously stages of the pharmacoeconomic study that had grounded the development of the tool were defined. 
The tool was designed with three fields: one static and two others to be filled by the user. The "accumulated inflation 
(base 2015)" is related to the accumulated inflation rate in years after 2015, because the estimated costs were based 
on that year. The "initial investment", in which the manager will put the intended amount of investment in structuring 
PC in a region or municipality. And finally, the "loss of resource", which will be filled automatically and will show 
how much of the value to be invested is obsolete, that is, the surplus of the investment. Thus, the manager can save or 
reallocate this resource, or make the decision to complement it and extend the scope of the PC in the municipality or 
region. The tool will then show financial and epidemiological impact estimations as well as its aid to health 
management 
The core of the pharmacoeconomic tool is web-based following the model-view-controller (MVC) pattern31. The 
MVC architecture organizes the application into three interconnected parts. The first, the model, represents an object 
carrying data. The second, the view, represents the presentation layer, where it is possible to visualize the data that 
the model contains. Finally, the controller acts on both model and view controlling the data flow updating the view 
whenever data changes. This pattern enables a better organization of the code and allows the development of multiple 
views for a model.  
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The tool will provide interoperability by a web service application program interface (API) that adhere to the 
representational state transfer (REST) architecture32. REST is also a pattern to provide easy access to the logic of the 
application and facilitates the integration with other systems.  
The API and the web tool will be implemented using the PHP framework CakePHP that makes building web 
applications using the MVC patterns and implementing REST services simpler, faster, while requiring less code33. 
The presentation layer will be developed using HTML5, CSS and JavaScript. Also, a mobile application will be 
developed and will uses the REST API. 
The main interface of the tool is presented in Fig. 2. 
 
 
Fig. 2 Main layout of the pharmacoeconomic tool to aid decision making by health managers for the implementing the care of hypertensive 
patients by Pharmaceutical Care. 
3.2. Systematic Review 
The systematic review will address the question: "What are the clinical outcomes regarding blood pressure, 
cholesterol, HDL and cardiovascular risk reached by pharmaceutical care in patients diagnosed with essential systemic 
arterial hypertension in treatment at the primary care?". The objective is to know the existing models of pharmaceutical 
care for hypertensive patients, summarizing the clinical results achieved by this technology in health.  
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3.3. Human Network Disease and projection of the diseases associated with the complications of SAH 
The projection of the morbidities associated with SAH and its complications will be performed by a hypothetical 
cohort in Markov modeling, which will be distinguished between health care without and with Pharmaceutical Care. 
Each group will have the peculiarity of the difference in the number of patients with SAH complications. The health 
states will be defined as: Stable (under treatment for HAS); Morbidity (in treatment of the complication of SAH); 
Death (state of absorption). Patients with SAH complications will be likely to remain stable, in treatment for the 
complication, to present the morbidity associated with the complication or to die due to the complication. Those who 
present the associated morbidity will be likely to remain stable in morbidity treatment or die due to the morbidity. 
Thus, patients will transit between the three Markov health states along ten Markov cycles, which represent ten years 
of projection, according to the methodology developed for the elaboration of the pharmacoeconomic tool23,24,25,34,35,36. 
The probabilities will be acquired by the Delphi method, a systematic method of judging information, used to 
obtain the consensus opinion of experts on a given subject. This method was chosen because studies on Human 
Networks diseases are incipient and the literature is poor in epidemiological and statistical information for calculating 
probabilities. A form will be drawn up for collecting epidemiological information from the specialists and then the 
probabilities to be assigned to Markov modeling will be calculated. For this purpose, this study predicts collaboration 
on the knowledge of a group of experts in CVDs and SAH37 that will judge the information. A Markov model will be 
structured for each known complication of SAH for the development of the pharmacoeconomic tool (Chronic Renal 
Disease, Heart Failure, Ischemic Heart Disease, Stroke and Peripheral Arterial Disease). 
The diseases associated with the complications of hypertension will be listed according to the studies on Human 
Networks diseases. The cost of each morbidity associated with hypertension will be obtained by the SIH and SIASUS. 
These systems integrate the TabWin database of the Brazilian Department of Informatics, DATASUS38.  
3.4. Validation of the pharmacoeconomic tool 
A questionnaire with three domains will be elaborated to validate the tool, namely the applicability in the 
management practice; the layout and understanding of the information; and the contentment with the tool and its 
reliability39. This questionnaire will be appreciated by a group of ten judges, chosen as experts in management or in 
economics. The suggestions and observations of the experts will be discussed and the questionnaire will be 
reformulated until the instrument does not require further corrections by the specialists. It is noteworthy that for 
validation studies, there is no consensus for the determination of the sample number, and the researcher is empirical 
to judge with observance and aptitude regarding the method used40,41. 
A tutorial will be prepared for the use of the tool after its restructuring. Therefore, a group of five public health 
managers will be invited to perform a previous training on the use of the tool and then test their use in a fictional case 
of public health management, to be elaborated specifically to this study. After using the tool and performing the 
situational case, managers will respond to the questionnaire previously validated on the pharmacoenomic tool42. 
According to the internal validity of the answers, it will be evaluated if the tool needs adjustments, which will be 
later reevaluated by the judges. With the tool validated for use, it is intended to disseminate it by scientific means and 
make it accessible to the practice of health management in Brazil. It should be noted that the elaborated 
pharmacoeconomic tool is in the process of patent application by the USP agency of innovation. Its disclosure and 
applicability will be made after registration of the copyright. 
3.5. Analysis of the results 
The analysis of the results will be through classic and Bayesian statistics. The Bayesian statistics will be used for 
the stage of the projection costs of diseases associated with HAS complications. The level of significance of 5% will 
be considered for both cases.  
For the systematic review, the agreement between the two researchers will be analyzed by the coefficient of Kappa, 
being acceptable the value above 0.80, otherwise a new search strategy will be restructured. The Mann-Whitney test 
will be performed to test the difference between the quality scores of studies in which PC has favorable and 
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unfavorable clinical results. Finally, the software SPSS version 19 will be used for the classical inferential statistical 
analysis.  
To design the morbidities associated with the complications of SAH, the software OpenBUGS version 3.2.3 will 
be used to perform the descriptive statistics from previous data, which correspond to the opinion of the experts 
obtained by the Delphi method. In this way, the prediction of the probability of SAH complications occurrence, as 
well as of the SAH associated diseases, will be measured to run the Markov model43. The sensitivity of the cost results 
will be analyzed using the software @Risk, considering the variation according to the distribution of probabilities of 
each cost variable to ten thousand iterations in the Monte Carlo simulation. 
Through the Cronbach’s alpha 44, the internal consistency of the validation questionnaire of the pharmacoeconomic 
tool will be analyzed by measuring the correlation between the responses. This method of analysis was chosen because 
the questionnaire to be elaborated presents more than two options as a response and will be applied only once. The 
objective is to demonstrate the trust and applicability of the tool for public management. 
4. Conclusion 
The proposed tool can enable the measurement of the epidemiological and economic impact of hypertension 
management by PC, but it should be emphasized that the tool is not 100% accurate, as well as many others that are 
used in management, because there may be variations in the economy capable of influencing health policies and 
access. These factors interfere in the quality of health care, which difficult the work of pharmacists and health 
professionals involved in the service, culminating in worse than expected clinical results. However, with the validation 
of this tool it will be possible to make it applicable to the management practice in health and, thus, to improve the 
pressure control index among hypertensive patients and the quality of life, as well as to reduce the morbidities 
associated with SAH, the complications associated with these morbidities, deaths, and overhead costs such as 
disability and death pension. In addition, the health planning promoted with the use of this tool will be able to optimize 
health resources, since the acquired savings can be reallocated in other assistance programs and in the care of more 
costly morbidities to SUS. Although the training of the pharmacist in Brazil is incipient for clinical practice, which 
may delay the implementation process of PC due to the lack of professional training to perform it, the development 
of this tool tends to assist in the process of change in the profession, in which it foresees the curricular change tending 
to the formation of more clinical character. In this sense, the use of the tool can subsidize decision making for the 
absorption of the pharmacist regarding the development of clinical practice in the labor market. In addition, it is hoped 
that this study will foster a possible subarea in pharmacoeconomics, the use of proteomics both for the incorporation 
of new technologies in SUS and for prevention planning and disease aggravations. In this context, the intention of this 
project is to contribute to the research, innovation of studies in the field and to the advances of science.  
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unfavorable clinical results. Finally, the software SPSS version 19 will be used for the classical inferential statistical 
analysis.  
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be used to perform the descriptive statistics from previous data, which correspond to the opinion of the experts 
obtained by the Delphi method. In this way, the prediction of the probability of SAH complications occurrence, as 
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health resources, since the acquired savings can be reallocated in other assistance programs and in the care of more 
costly morbidities to SUS. Although the training of the pharmacist in Brazil is incipient for clinical practice, which 
may delay the implementation process of PC due to the lack of professional training to perform it, the development 
of this tool tends to assist in the process of change in the profession, in which it foresees the curricular change tending 
to the formation of more clinical character. In this sense, the use of the tool can subsidize decision making for the 
absorption of the pharmacist regarding the development of clinical practice in the labor market. In addition, it is hoped 
that this study will foster a possible subarea in pharmacoeconomics, the use of proteomics both for the incorporation 
of new technologies in SUS and for prevention planning and disease aggravations. In this context, the intention of this 
project is to contribute to the research, innovation of studies in the field and to the advances of science.  
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